- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT04491942
요로상피암에 중점을 둔 진행성 고형 종양에 대한 일반 화학요법 치료(시스플라틴 또는 시스플라틴 및 젬시타빈)에 대한 항암제 BAY 1895344의 추가 테스트
요로상피암에 중점을 둔 진행성 고형 종양에서 ATR 억제제 BAY 1895344와 시스플라틴 및 시스플라틴 플러스 젬시타빈 병용의 1상 시험
This phase I trial identifies the best dose, possible benefits and/or side effects of BAY 1895344 in combination with chemotherapy in treating patients with solid tumors or urothelial cancer that has spread to other places in the body (advanced). BAY 1895344 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Cisplatin and gemcitabine are chemotherapy drugs that stop the growth of tumor cells by killing the cells. Combining BAY 1895344 with chemotherapy treatment (cisplatin, or cisplatin and gemcitabine) may be effective for the treatment of advanced solid tumors, including urothelial cancer.
연구 개요
상태
정황
- 해부학적 III기 유방암 AJCC v8
- 해부학적 4기 유방암 AJCC v8
- 진행성 악성 고형 신생물
- 3기 폐암 AJCC v8
- IV기 폐암 AJCC v8
- 임상 3기 위암 AJCC v8
- 임상 IV기 위암 AJCC v8
- 삼중음성 유방암
- 4기 음경암 AJCC v8
- 진행성 위암
- 진행성 유방암
- 3기 자궁경부암 AJCC v8
- IV기 자궁경부암 AJCC v8
- 진행성 폐 비소세포 암종
- 3기 난소암 AJCC v8
- IV기 난소암 AJCC v8
- 진행성 난소암
- 절제 불가능한 요로상피암
- 진행된 두경부 암종
- 진행성 폐 소세포 암종
- 진행성 요로상피암
- IV기 원위 담관암 AJCC v8
- IV기 간내 담관암 AJCC v8
- 진행성 식도암
- 진행된 자궁내막 암종
- 진행성 흉막 악성 중피종
- III기 원위 담관암 AJCC v8
- 진행성 담관 암종
- 진행성 자궁경부암
- 진행성 음경 암종
- 3기 간내 담관암 AJCC v8
- 3기 음경암 AJCC v8
- 3기 흉막 미만성 악성 중피종 AJCC v8
- AJCC v8 분류 제4기 흉막 확산성 악성 중피종
상세 설명
PRIMARY OBJECTIVES:
I. To establish the safety and tolerability of the combination of cisplatin + elimusertib (BAY 1895344) in patients with advanced solid tumors.
II. To establish the safety and tolerability of the combination of cisplatin + gemcitabine + BAY 1895344 in patients with advanced solid tumors with an emphasis on urothelial carcinoma (UC).
III. To establish the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of cisplatin + BAY 1895344 and cisplatin + gemcitabine + BAY 1895344.
SECONDARY OBJECTIVES:
I. To evaluate the pharmacokinetic profile of BAY 1895344 (in the doublet and triplet combinations) and gemcitabine (in the triplet) in combination with cisplatin.
II. To further evaluate the toxicity of the combination of cisplatin + gemcitabine + BAY 1895344 in patients with UC.
III. To evaluate preliminary efficacy observed with cisplatin + BAY 1895344 and cisplatin + gemcitabine + BAY 1895344 in patients with advanced solid tumors, including UC.
EXPLORATORY OBJECTIVES:
I. To evaluate the correlation of biomarkers, including deleterious deoxyribonucleic acid (DNA) damage response (DDR) gene alterations and circulating tumor (ct)DNA with responses to therapy using whole exome sequencing (WES) and messenger ribonucleic acid sequencing (RNA seq) analysis of archival formalin fixed paraffin embedded (FFPE) tissue, as well as blood.
II. To correlate drug exposure with response and/or toxicity.
OUTLINE: This is a dose-escalation study of elimusertib. Patients are assigned to 1 of 2 arms.
ARM I (DOUBLET COMBINATION): Patients receive cisplatin intravenously (IV) over 1-2 hours on day 1 and 8, and elimusertib orally (PO) once daily (QD) on days 2 and 9. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
ARM II (TRIPLET COMBINATION): Patients receive cisplatin IV over 1-2 hours on day 1 and 8, gemcitabine IV over 30 minutes on days 1 and 8, and elimusertib PO QD on days 2 and 9. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 30 days, then every 3 months thereafter.
연구 유형
등록 (추정된)
단계
- 1단계
연락처 및 위치
연구 장소
-
-
California
-
Sacramento, California, 미국, 95817
- University of California Davis Comprehensive Cancer Center
-
-
Maryland
-
Bethesda, Maryland, 미국, 20892
- National Institutes of Health Clinical Center
-
Bethesda, Maryland, 미국, 20892
- National Cancer Institute Developmental Therapeutics Clinic
-
-
New York
-
New York, New York, 미국, 10032
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
-
-
Ohio
-
Columbus, Ohio, 미국, 43210
- Ohio State University Comprehensive Cancer Center
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, 미국, 15232
- UPMC Hillman Cancer Center
-
-
Wisconsin
-
Madison, Wisconsin, 미국, 53792
- University of Wisconsin Carbone Cancer Center - University Hospital
-
-
-
-
Ontario
-
Toronto, Ontario, 캐나다, M5G 2M9
- University Health Network-Princess Margaret Hospital
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
-
Histologically-confirmed advanced solid tumor with measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1 criteria, for which cisplatin-based therapy would be considered appropriate, including:
- Non-small cell lung cancer (NSCLC)
- UC
- Penile cancer
- Malignant pleural mesothelioma
- Small cell lung cancer
- Biliary tract cancer
- Esophageal and gastric cancers
- Ovarian cancer
- Endometrial cancer
- Cervical cancer
- Head and neck cancer
- Triple-negative breast cancer (Her2/neu-negative, estrogen receptor [ER]/progesterone receptor [PR]-negative breast cancer)
-
For the expansion cohort of the triplet combination at MTD/RP2D only:
- Patients with histologically confirmed advanced or unresectable urothelial carcinoma are eligible
- The histology should be predominantly urothelial (>= 50% of sample evaluated contains urothelial histology)
-
Age >= 18 years. Because no dosing or adverse event data are currently available on the use of BAY 1895344 in combination with gemcitabine and cisplatin in patients < 18 years of age, children are excluded from this study
-
Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)
-
Availability of archival FFPE tissue
-
Prior cisplatin exposure of < 300 mg/m^2. Patients with prior cisplatin treatment must have received last cisplatin treatment > 6 months prior to enrollment
-
Prior treatment with PARP inhibitors is permitted (such as olaparib, rucaparib, or other experimental inhibitors of PARP administered in a clinical trial)
-
Prior immune checkpoint inhibitor therapy is permitted (including anti-programmed cell death protein 1 [PD-1], anti-PD-ligand [L]1 therapy, such as pembrolizumab, nivolumab, avelumab, durvalumab, atezolizumab, or anti-cytotoxic t-lymphocyte protein 4 [CTLA4] therapy such as ipilimumab, or other experimental immune checkpoint pathway inhibitors administered in a clinical trial)
-
Leukocytes >= 3,000/mcL
-
Hemoglobin >= 9 g/dL
-
Neutrophil count >= 1,500/mcL
-
Platelets >= 100,000/mcL
-
Total bilirubin =< 2 mg/dL
-
Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 3 x institutional upper limit of normal (ULN)
-
Creatinine clearance >= 40 mL/min OR glomerular filtration rate (GFR) >= 40 mL/min/1.73 m^2 unless data exists supporting safe use at lower kidney function values, no lower than 30 mL/min/1.73 m^2
-
Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
-
For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
-
Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.
-
Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression
-
Patients with new or progressive brain metastases (active brain metastases) or leptomeningeal disease are eligible if the treating physician determines that immediate CNS specific treatment is not required and is unlikely to be required during the first cycle of therapy; patients with stable brain metastases that are asymptomatic and on a stable dose of steroids are also considered eligible
-
Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional classification. To be eligible for this trial, patients should be class 2B or better
-
The effects of BAY 1895344, cisplatin, and gemcitabine on the developing human fetus are unknown. For this reason and because deoxyribonucleic acid (DNA)-damage response inhibitors agents as well as other therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation and for 6 months after completion of BAY 1895344 administration. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 6 months after completion of BAY 1895344 administration
-
Ability to understand and the willingness to sign a written informed consent document
Exclusion Criteria:
- Life expectancy < 6 weeks by investigator assessment
- Other active malignancy requiring treatment, except for cutaneous malignancies that require resection such as squamous cell carcinoma, basal cell carcinoma, or cutaneous melanoma, and except for prostate cancer if only on androgen deprivation therapy
- Significant peripheral neuropathy (grade 2 or higher by Common Terminology Criteria for Adverse Events [CTCAE])
- Sensorineural hearing loss (grade 2 or higher by CTCAE)
- Must NOT have had prior treatment with ATR inhibitor (prior BAY1895344 or other investigational ATR inhibitors), or current treatment with any other investigational agents
- Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study. Patients who have targeted therapies (such as PARP inhibitors) within 2 weeks prior to entering the study
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to BAY 1895344 or other agents used in study
- Patients receiving any medications that are substrates of CYP3A4 with a narrow therapeutic window, or strong inhibitors/inducers of CYP3A4 are ineligible, if they cannot be transferred to alternative medication. Because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated medical reference. As part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product
- Patients with uncontrolled intercurrent illness
- Patients with psychiatric illness/social situations that would limit compliance with study requirements
- Pregnant women are excluded from this study because BAY 1895344 as a DNA-damage response inhibitor, cisplatin, and gemcitabine may have the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with BAY 1895344 breastfeeding should be discontinued if the mother is treated with BAY 1895344 and for 4 months after end of treatment. These potential risks may also apply to other agents used in this study
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Arm I (cisplatin, elimusertib)
Patients receive cisplatin IV over 1-2 hours on day 1 and 8, and elimusertib PO QD on days 2 and 9. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. |
Given IV
다른 이름들:
Given PO
다른 이름들:
|
|
실험적: Arm II (cisplatin, gemcitabine, elimusertib)
Patients receive cisplatin IV over 1-2 hours on day 1 and 8, gemcitabine IV over 30 minutes on days 1 and 8, and elimusertib PO QD on days 2 and 9. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. |
Given IV
다른 이름들:
Given IV
다른 이름들:
Given PO
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
BAY 1895344의 권장 2상 용량(RP2D)
기간: 치료 시작일로부터 21일 이내
|
치료 시작일로부터 21일 이내
|
|
|
Incidence of adverse events
기간: Up to 28 days after completion of study treatment
|
Toxicities will be tabulated and reported according to dose level, grade, type, cycle, and attribution. Tables will be created to summarize these toxicities and side effects, overall and by cohort. Proportions and associated 95% confidence intervals will be calculated for each cohort separately. Cumulative incidence curves will be used to estimate the proportion of patients who will discontinue therapy for reasons of toxicity or general inability to tolerate the regimen. |
Up to 28 days after completion of study treatment
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Pharmacokinetic (PK) parameter - maximum concentration (Cmax)
기간: Day 2 and day 9 after treatment start date
|
Estimated using non-compartmental methods. The PK variables will be tabulated and descriptive statistics (e.g., geometric means and coefficients of variation) calculated for each dose level. PK parameters will be reported descriptively for exploratory comparison with historical data (gemcitabine). |
Day 2 and day 9 after treatment start date
|
|
PK parameter - area under the concentration-time curve (AUC)
기간: Day 2 and day 9 after treatment start date
|
Estimated using non-compartmental methods. The PK variables will be tabulated and descriptive statistics (e.g., geometric means and coefficients of variation) calculated for each dose level. PK parameters will be reported descriptively for exploratory comparison with historical data (gemcitabine). The impact of cisplatin on BAY 1895344 exposure will be evaluated by calculation of the AUC ratio of (day 9 / day 2) and testing non-parametrically with a null hypothesis of a ratio = 1. |
Day 2 and day 9 after treatment start date
|
|
Deoxyribonucleic acid (DNA) damage repair (DDR) mutations
기간: Up to 2 years
|
The association between DDR mutations and responses will be described, with a table outlining patients who achieved by progressive disease, stable disease, partial or complete responses and DDR mutation status. |
Up to 2 years
|
|
Response rate
기간: Up to 2 years
|
The percent of responders will be calculated and associated exact 95% confidence intervals will be constructed. |
Up to 2 years
|
|
Progression-free survival (PFS)
기간: Up to 2 years
|
Kaplan-Meier plots will be used to summarize PFS. |
Up to 2 years
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Mamta Parikh, City of Hope Comprehensive Cancer Center LAO
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
- 비뇨생식기 질환
- 생식기 질환
- 내분비계 질환
- 생식기 신생물, 남성
- 비뇨생식기 신생물
- 부위별 신생물
- 신생물
- 생식기 질환, 남성
- 남성 비뇨 생식기 질환
- 여성 비뇨 생식기 질환
- 여성 비뇨 생식기 질환 및 임신 합병증
- 호흡기 질환
- 조직학적 유형에 따른 신생물
- 자궁 질환
- 생식기 질환, 여성
- 폐 질환
- 내분비샘 신생물
- 신생물, 선상 및 상피
- 호흡기 신생물
- 흉부 신생물
- 난소 질환
- 부속기 질환
- 생식기 신생물, 여성
- 생식선 장애
- 선종
- 신생물, 중피
- 흉막 신 생물
- 피부병
- 유방 질환
- 자궁 경부 질환
- 자궁 신생물
- 유방 신생물
- 음경 질환
- 피부 및 결합 조직 질환
- 중피종
- 중피종, 악성
- 폐 신생물
- 난소 신생물
- 자궁경부 신생물
- 삼중 음성 유방 신생물
- 음경 신생물
- 이종 사이 클릭 화합물, 1- 링
- 이종 사이 클릭 화합물
- 무기 화학 물질
- 염소 화합물
- 질소 화합물
- 데 옥시 시티 딘
- 시티 딘
- 피리 미딘 뉴 클레오 시드
- 피리 미딘
- 강요
- 궤조
- 금속, 무겁다
- 백금 화합물
- 전환 요소
- 젬시타빈
- 시스플라틴
- 1,2-디아미노사이클로헥산백금 II 구연산염
- 백금
- 베이 1895344
기타 연구 ID 번호
- NCI-2020-05428
- UM1CA186717 (미국 NIH 보조금/계약)
- NCI-2020-05428 (레지스트리 식별자: CTRP (Clinical Trial Reporting Program))
- PHI-117
- 10404 (기타 식별자: CTEP)
- 10404 (기타 식별자: City of Hope Comprehensive Cancer Center LAO)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .